Key Takeaways & Executive Findings
- •• The US regulatory framework provides more streamlined pathways and incentives for drug repurposing compared to the EU and Japan. • The EU and Japan have unique mechanisms, such as the adaptive pathways and Sakigake designation, that can be leveraged for repurposing. • Regulatory harmonization and enhanced collaboration can accelerate drug repurposing for rare diseases globally. • The study proposes actionable recommendations to improve regulatory frameworks and patient access to repurposed drugs.
Abstract
Rare diseases affect millions worldwide, yet treatment options remain limited. Drug repurposing offers a promising strategy to accelerate therapeutic development. This study provides a comprehensive comparative analysis of regulatory frameworks for drug repurposing in the United States, European Union, and Japan. We examine the regulatory pathways, incentives, and challenges for repurposing existing drugs for rare diseases. Our findings reveal significant differences in regulatory approaches, with the US offering more streamlined pathways and incentives, while the EU and Japan have unique mechanisms that can be leveraged. We propose recommendations to harmonize and enhance global regulatory frameworks to facilitate drug repurposing and improve patient access to treatments for rare diseases.
1. Introduction
Rare diseases, also known as orphan diseases, affect a small percentage of the population but collectively impact millions of individuals worldwide. Despite advances in biomedical research, the development of treatments for rare diseases remains a significant challenge due to high costs, limited patient populations, and scientific complexities. Drug repurposing, the process of identifying new therapeutic uses for existing drugs, has emerged as a promising strategy to accelerate the availability of treatments for rare diseases. By leveraging existing safety and pharmacokinetic data, repurposing can reduce development time and costs, offering a faster route to patients in need.
Regulatory frameworks play a crucial role in facilitating or hindering drug repurposing. Different countries have established various pathways, incentives, and requirements for the approval of repurposed drugs. Understanding these regulatory landscapes is essential for developers and policymakers to optimize strategies for bringing repurposed drugs to market. This paper provides a comparative analysis of the regulatory frameworks for drug repurposing in the United States, European Union, and Japan, highlighting key similarities, differences, and opportunities for improvement.
Loading authentic research manuscript (Pages 1–5)...
John Smith, Jane Doe, Robert Johnson (2026). Regulatory Review and Drug Repurposing for Rare Diseases: A Comparative Analysis of the United States, European Union, and Japan. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-025-00001-2
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is drug repurposing?
Drug repurposing, also known as drug repositioning, is the process of identifying new therapeutic uses for existing approved drugs. This strategy can accelerate drug development by leveraging existing safety and pharmacokinetic data, reducing time and costs compared to de novo drug development.
Why is drug repurposing important for rare diseases?
Rare diseases often have limited treatment options due to small patient populations and high development costs. Drug repurposing offers a faster and more cost-effective pathway to bring treatments to patients, as the safety profile of the drug is already established.
What are the key regulatory pathways for drug repurposing in the US?
In the US, the FDA provides several pathways for drug repurposing, including the 505(b)(2) application, which allows reliance on data not developed by the applicant, and the Orphan Drug Designation, which offers incentives such as tax credits and market exclusivity.
How does the EU regulatory framework support drug repurposing?
The European Medicines Agency (EMA) offers the adaptive pathways approach and the PRIME scheme, which facilitate early and iterative development of medicines, including repurposed drugs. Additionally, the EU's orphan regulation provides incentives for rare disease treatments.
What is the Sakigake designation in Japan?
The Sakigake designation is a Japanese regulatory scheme that provides priority review and enhanced support for innovative drugs, including repurposed drugs, that address unmet medical needs. It aims to accelerate patient access to breakthrough therapies.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.